Het is goedgekeurd voor het gebruik bij babys en kinderen
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Using both approaches mindfully can give your skin the care it needs
The available scientific data describe retatrutyd as a molecule with a triple receptor profile, making it an interesting research model for studies into the pharmacology of metabolic peptides and incretin receptors
Areas of interest include, but are not limited to: Classic antidiabetic, anti-obesity and cardioprotective effects Cardiovascular outcomes and mechanistic correlates Endothelial and vascular biology Myocardial metabolism and heart failure subtypes Novel renal and hepatoprotective actions Optimization and individualized use of existing GLP-1 receptor agonists Development of novel GLP-1 receptor agonists and multi-agonist (dual and triple) strategies Emerging extra-metabolic actions, including anti-inflammatory and neuroprotective effects Combination therapies, including co-formulations with insulin or SGLT2 inhibitors Innovative delivery systems, including non-injectable and implantable approaches Real-world comparative effectiveness, long-term safety, adherence and treatment durability This Collection welcomes original research, translational studies, and comprehensive reviews and meta-analyses that provide novel mechanistic insight or clinically relevant evidence to advance understanding of the expanding role of incretin-based therapies in cardiometabolic medicine
Sections (35 m) of paraffin-embedded tissues were dewaxed in xylene and rehydrated through a graded series of ethanol and double distilled water
